Rational Design of Potent Peptide Inhibitors of the PD-1:PD-L1 Interaction for Cancer Immunotherapy
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Peptides have potential to be developed into immune checkpoint inhibitors, but the target interfaces are difficult to inhibit. Here, we explored an approach to mimic the binding surface of PD-1 to design inhibitors. Mimicking native PD-1 resulted in a mimetic with no activity. However, mimicking an affinity-optimized PD-1 resulted in the peptide mimetic MOPD-1 that displayed nanomolar affinity to PD-L1 and could inhibit PD-1:PD-L1 interactions in both protein- and cell-based assays. Mutagenesis and structural characterization using NMR spectroscopy and X-ray crystallography revealed that binding residues from the high affinity PD-1 are crucial for the bioactivity of MOPD-1. Furthermore, MOPD-1 was extremely stable in human serum and inhibited tumor growth in vivo, suggesting it has potential for use in cancer immunotherapy. The successful design of an inhibitor of PD-1:PD-L1 using the mimicry approach described herein illustrates the value of placing greater emphasis on optimizing the target interface before inhibitor design and is an approach that could have broader utility for the design of peptide inhibitors for other complex protein–protein interactions.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Conceivable data revealed abolished PD‐1 and PD‐L1 interactions, improved T‐cell activity, and enhanced antitumor immunity in colon, breast, pancreatic, and kidney cancer models [338, 339, 340, 341].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [338]
Citations
Cites
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
1H, 13C and 15N chemical shift referencing in biomolecular NMR
Wishart, D. S., Bigam, C. G., Yao, J., Abildgaard, F., Dyson, H. J., Oldfield, E., Markley, J. L., & Sykes, B. D. (1995) · Journal of Biomolecular NMR · doi:10.1007/bf00211777 · Cited by 2,359
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345
Couzin-Frankel, J. (2013) · Science · doi:10.1126/science.342.6165.1432 · Cited by 2,051
The Future of Peptide‐based Drugs
Craik, D. J., Fairlie, D. P., Liras, S., & Price, D. (2013) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12055 · Cited by 1,979
Self-citationA Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Sanmamed, M. F., & Chen, L. (2018) · Cell · doi:10.1016/j.cell.2018.09.035 · Cited by 1,392
Pelay‐Gimeno, M., Glas, A., Koch, O., & Grossmann, T. N. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201412070 · Cited by 717
Chang, Y. S., Graves, B., Guerlavais, V., Tovar, C., Packman, K., To, K.-H., Olson, K. A., Kesavan, K., Gangurde, P., Mukherjee, A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303002110 · Cited by 660
Cancer immunotherapies targeting the PD-1 signaling pathway
Iwai, Y., Hamanishi, J., Chamoto, K., & Honjo, T. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0329-9 · Cited by 635
Cancer Immunotherapy Comes of Age
Topalian, S. L., Weiner, G. J., & Pardoll, D. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0899 · Cited by 586
Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1
Zak, K. M., Kitel, R., Przetocka, S., Golik, P., Guzik, K., Musielak, B., Dömling, A., Dubin, G., & Holak, T. A. (2015) · Structure · doi:10.1016/j.str.2015.09.010 · Cited by 531
Structural and Functional Analysis of the Costimulatory Receptor Programmed Death-1
Zhang, X., Schwartz, J.-C. D., Guo, X., Bhatia, S., Cao, E., Chen, L., Zhang, Z.-Y., Edidin, M. A., Nathenson, S. G., & Almo, S. C. (2004) · Immunity · doi:10.1016/s1074-7613(04)00051-2 · Cited by 410
Blocking of the PD‐1/PD‐L1 Interaction by a D‐Peptide Antagonist for Cancer Immunotherapy
Chang, H., Liu, B., Qi, Y., Zhou, Y., Chen, Y., Pan, K., Li, W., Zhou, X., Ma, W., Fu, C., et al. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201506225 · Cited by 397
Self-citationTargeted glycan degradation potentiates the anticancer immune response in vivo
Gray, M. A., Stanczak, M. A., Mantuano, N. R., Xiao, H., Pijnenborg, J. F. A., Malaker, S. A., Miller, C. L., Weidenbacher, P. A., Tanzo, J. T., Ahn, G., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0622-x · Cited by 362
Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging
Maute, R. L., Gordon, S. R., Mayer, A. T., McCracken, M. N., Natarajan, A., Ring, N. G., Kimura, R., Tsai, J. M., Manglik, A., Kruse, A. C., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1519623112 · Cited by 347
HIP1R targets PD-L1 to lysosomal degradation to alter T cell–mediated cytotoxicity
Wang, H., Yao, H., Li, C., Shi, H., Lan, J., Li, Z., Zhang, Y., Liang, L., Fang, J.-Y., & Xu, J. (2019) · Nature Chemical Biology · doi:10.1038/s41589-018-0161-x · Cited by 325
Structure and Interactions of the Human Programmed Cell Death 1 Receptor
Cheng, X., Veverka, V., Radhakrishnan, A., Waters, L. C., Muskett, F. W., Morgan, S. H., Huo, J., Yu, C., Evans, E. J., Leslie, A. J., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.448126 · Cited by 323
Current strategies in extending half-lives of therapeutic proteins
Zaman, R., Islam, R. A., Ibnat, N., Othman, I., Zaini, A., Lee, C. Y., & Chowdhury, E. H. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.02.016 · Cited by 278
Cancer immunotherapy: The past, the present and the future
Parish, C. R. (2003) · Immunology & Cell Biology · doi:10.1046/j.0818-9641.2003.01151.x · Cited by 239
A RaPID way to discover nonstandard macrocyclic peptide modulators of drug targets
Passioura, T., & Suga, H. (2017) · Chemical Communications · doi:10.1039/c6cc06951g · Cited by 193
Bioactive Macrocyclic Inhibitors of the PD‐1/PD‐L1 Immune Checkpoint
Magiera‐Mularz, K., Skalniak, L., Zak, K. M., Musielak, B., Rudzinska‐Szostak, E., Berlicki, Ł., Kocik, J., Grudnik, P., Sala, D., Zarganes‐Tzitzikas, T., et al. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201707707 · Cited by 175
Releasing the Brakes on Cancer Immunotherapy
Littman, D. R. (2015) · Cell · doi:10.1016/j.cell.2015.08.038 · Cited by 166
A Novel d‐Peptide Identified by Mirror‐Image Phage Display Blocks TIGIT/PVR for Cancer Immunotherapy
Zhou, X., Zuo, C., Li, W., Shi, W., Zhou, X., Wang, H., Chen, S., Du, J., Chen, G., Zhai, W., et al. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202002783 · Cited by 165
Self-citationProgress in PD-1/PD-L1 pathway inhibitors: From biomacromolecules to small molecules
Lin, X., Lu, X., Luo, G., & Xiang, H. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111876 · Cited by 160
Immune Checkpoint PD‐1/PD‐L1: Is There Life Beyond Antibodies?
Konstantinidou, M., Zarganes‐Tzitzikas, T., Magiera‐Mularz, K., Holak, T. A., & Dömling, A. S. S. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201710407 · Cited by 147
Proteomimetics as protein-inspired scaffolds with defined tertiary folding patterns
Horne, W. S., & Grossmann, T. N. (2020) · Nature Chemistry · doi:10.1038/s41557-020-0420-9 · Cited by 146
Fmoc-Based Synthesis of Disulfide-Rich Cyclic Peptides
Cheneval, O., Schroeder, C. I., Durek, T., Walsh, P., Huang, Y., Liras, S. I., Price, D. A., & Craik, D. J. (2014) · The Journal of Organic Chemistry · doi:10.1021/jo500699m · Cited by 125
Self-citationRational Design of Topographical Helix Mimics as Potent Inhibitors of Protein–Protein Interactions
Lao, B. B., Drew, K., Guarracino, D. A., Brewer, T. F., Heindel, D. W., Bonneau, R., & Arora, P. S. (2014) · Journal of the American Chemical Society · doi:10.1021/ja502310r · Cited by 125
Wang, T., Wu, X., Guo, C., Zhang, K., Xu, J., Li, Z., & Jiang, S. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00990 · Cited by 124
Checco, J. W., Kreitler, D. F., Thomas, N. C., Belair, D. G., Rettko, N. J., Murphy, W. L., Forest, K. T., & Gellman, S. H. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1420380112 · Cited by 119
Human and mouse PD-L1: similar molecular structure, but different druggability profiles
Magiera‐Mularz, K., Kocik-Krol, J., Musielak, B., Plewka, J., Sala, D., Machula, M., Grudnik, P., Hajduk, M., Czepiel, M., Siedlar, M., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101960 · Cited by 109
Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant
Pascolutti, R., Sun, X., Kao, J., Maute, R. L., Ring, A. M., Bowman, G. R., & Kruse, A. C. (2016) · Structure · doi:10.1016/j.str.2016.06.026 · Cited by 102
Bottom-up de novo design of functional proteins with complex structural features
Yang, C., Sesterhenn, F., Bonet, J., van Aalen, E. A., Scheller, L., Abriata, L. A., Cramer, J. T., Wen, X., Rosset, S., Georgeon, S., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-020-00699-x · Cited by 84
An Effective Strategy for Stabilizing Minimal Coiled Coil Mimetics
Wuo, M. G., Mahon, A. B., & Arora, P. S. (2015) · Journal of the American Chemical Society · doi:10.1021/jacs.5b05525 · Cited by 82
Programmed Death‐1: Therapeutic Success after More than 100 Years of Cancer Immunotherapy
Dömling, A. S. S., & Holak, T. A. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307906 · Cited by 72
Protein epitope mimetic macrocycles as biopharmaceuticals
Luther, A., Moehle, K., Chevalier, É., Dale, G. E., & Obrecht, D. (2017) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2017.02.004 · Cited by 66
Wendt, M., Bellavita, R., Gerber, A., Efrém, N., van Ramshorst, T., Pearce, N. M., Davey, P. R. J., Everard, I., Vazquez‐Chantada, M., Chiarparin, E., et al. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202102082 · Cited by 64
Computational design of a synthetic PD-1 agonist
Bryan, C. M., Rocklin, G. J., Bick, M. J., Ford, A., Majri-Morrison, S., Kroll, A. V., Miller, C. J., Carter, L., Goreshnik, I., Kang, A., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2102164118 · Cited by 61
Optimization of the cyclotide framework to improve cell penetration properties
Huang, Y., Chaousis, S., Cheneval, O., et al. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00017 · Cited by 48
Self-citationEngineered protein scaffolds as leads for synthetic inhibitors of protein–protein interactions
Wuo, M. G., & Arora, P. S. (2018) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2018.05.013 · Cited by 30
Tombling, B. J., Lammi, C., Lawrence, N., Gilding, E. K., Grazioso, G., Craik, D. J., & Wang, C. K. L. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01766 · Cited by 25
Self-citationAn Integrated Molecular Grafting Approach for the Design of Keap1-Targeted Peptide Inhibitors
Yin, H., Huang, Y., Best, S. A., Sutherland, K. D., Craik, D. J., & Wang, C. K. L. (2021) · ACS Chemical Biology · doi:10.1021/acschembio.1c00388 · Cited by 20
Self-citationKamalinia, G., Engel, B. J., Srinivasamani, A., Grindel, B. J., Ong, J. N., Curran, M. A., Takahashi, T. T., Millward, S. W., & Roberts, R. W. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00264 · Cited by 15
Cited by
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
Design of Cyclic Peptides Targeting Protein–Protein Interactions Using AlphaFold
(2023) · doi:10.3390/ijms241713257 · Cited by 51
Fast, accurate ranking of engineered proteins by target-binding propensity using structure modeling
Ding, X., Chen, X., Sullivan, E. E., Shay, T. F., & Gradinaru, V. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.04.003 · Cited by 20
Metadata
- Authors
- Yin, H., Zhou, X., Huang, Y.-H., King, G. J., Collins, B. M., Gao, Y., Craik, D. J., & Wang, C. K.
- Affiliations
- The University of Queensland (AU)
- Zhengzhou University (CN)
- Sun Yat-sen University (CN)
- Corresponding author
- Craik, David J.
- Wang, Conan K.
- ORCID
- Venue
- Journal of the American Chemical Society
- Publisher
- American Chemical Society (ACS)
- Published
- 2021-10-18
- Volume
- 143
- Issue
- 44
- Pages
- 18536-18547
- ISSN
- 0002-7863 (ISSN-L)
- 1520-5126
- OpenAlex
- W3207145203
- Cited by
- 57
- References
- 49
- Citations by year
- 2026: 8 · 2025: 14 · 2024: 16 · 2023: 10 · 2022: 9
- FWCI
- 2.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Journal of the American Chemical Society (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Health and Medical Research Council (APP1084965, APP1136021)
- Australian Research Council (FL150100146)
- China Scholarship Council
- National Natural Science Foundation of China (U20A20369)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Keywords
- PD-1/PD-L1 interaction, peptide inhibitors, immune checkpoint inhibitors, cancer immunotherapy, protein-protein interaction inhibition, serum stability, tumor growth inhibition, structure-based inhibitor design
- MeSH terms
- Immune Checkpoint Inhibitors, Amino Acid Sequence, Animals, Antineoplastic Agents, Female, Humans, Immunotherapy, Mice, Inbred BALB C, Neoplasms, Neoplasms, Experimental, Mice, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.